caa a22 4500 477056695 CHVBK 20180405111347.0 cr unu---uuuuu 170330e19960901xx s 000 0 eng 10.1007/s002280050153 doi (NATIONALLICENCE)springer-10.1007/s002280050153 Nucleoside transport inhibition by draflazine in unstable coronary disease [Elektronische Daten] [K. Andersen, M. Dellborg, K. Swedberg] Objectives In a randomised, double-blind, placebo controlled study, we evaluated the tolerability and safety of draflazine, a nucleoside transport inhibitor, in the treatment of patients with unstable angina and non-Q-wave infarction. Methods Twenty-one patients were randomised to treatment with draflazine 3.5 mg or matching placebo given as an IV infusion and haemodynamic and symptomatic tolerability were investigated. Myocardial ischaemia was evaluated by means of vectorcardiography and blood analysis of the MB fraction of creatine kinase. Results The study drug was well tolerated by all patients and it did not cause any adverse haemodynamic effects, nor other serious adverse events. Three patients in the placebo group reported five adverse events, as compared to a single adverse event in the draflazine group. Cardiovascular events were detected in 7 patients in the placebo group and in 5 patients receiving draflazine. The mean duration of chest pain during the 24 hour observation period was 91.4 min in the placebo group compared to 75.5 min in draflazine treated patients. Neither the vectorcardiographic nor biochemical measures of ischaemia differed between treatment groups. Conclusion Nucleoside transport inhibition by draflazine was well tolerated by patients with unstable coronary disease. It seems to be a promising method of adenosine enhancement in acute myocardial ischaemia. The potential cardioprotective effect of the drug needs further evaluation in larger trials. Springer-Verlag Berlin Heidelberg, 1996 Key words Nucleoside transport inhibitors nationallicence Angina pectoris nationallicence unstable angina nationallicence adenosine nationallicence ischaemia nationallicence vectorcardiography nationallicence draflazine nationallicence Andersen K. Department of Medicine, Östra University Hospital, S-416 85 Göteborg, Sweden, SE aut Dellborg M. Department of Medicine, Östra University Hospital, S-416 85 Göteborg, Sweden, SE aut Swedberg K. Department of Medicine, Östra University Hospital, S-416 85 Göteborg, Sweden, SE aut https://doi.org/10.1007/s002280050153 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050153 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Andersen K. Department of Medicine, Östra University Hospital, S-416 85 Göteborg, Sweden, SE aut NATIONALLICENCE 700 1- Dellborg M. Department of Medicine, Östra University Hospital, S-416 85 Göteborg, Sweden, SE aut NATIONALLICENCE 700 1- Swedberg K. Department of Medicine, Östra University Hospital, S-416 85 Göteborg, Sweden, SE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer